Summary A bispecific monoclonal antibody recognising both carcinoembryonic antigen (CEA) and ricin toxin A chain (RTA) was tested for its ability to target recombinant RTA (r-RTA) to CEA-expressing tumour cells, alone and in combination with ricin B chain (RTB). The antibody, 636 , induced significant RTA cytotoxicity against MKN45 gastric carcinoma cells which express high levels of CEA, using the r-RTA at a concentration below that known to be intrinsically cytotoxic. The addition of ricin toxin B chain (RTB) also potentiated cytotoxicity of r-RTA, and there was an additive increase in potentiation against CEA-positive cells when both RTB and 636 were included. The bispecific antibody restored potentiation by RTB after blocking of its binding site with excess galactose, and also the cytotoxic activity of whole ricin which had been blocked with galactose. (Raso & Griffin, 1981; Webb et al., 1985 Webb et al., , 1986 Glennie et al., 1988) .
Over the past decade there have been intensive efforts to exploit anti-tumour monoclonal antibodies for therapeutic use by using them to target cytotoxic agents to tumour cells. The greatest interest has been shown in targeted plant or bacterial toxins, which have the ability to kill eukaryotic cells in extremely low concentrations (Eiklid et al., 1980) . The best studied of such reagents had been the A chain sub-unit of ricin toxin (RTA) which has been made selectively cytotoxic in vitro for various tumour cell lines by chemical conjugation to a wide range of monoclonal antibodies to form immunotoxins (Fitzgerald & Pastan, 1989;  reviews in Davies & Crumpton, 1982; Moller, 1982) . Success in vivo has been more limited for a variety of reasons, notably the inappropriate biodistribution of free or conjugated toxins compared with free monoclonal antibodies (Simmons et al., 1986; Thorpe et al., 1985; Byers et al., 1987) , and their poor tissue penetration ability. An alternative approach to antibody targeting which may avoid or minimise some of these problems is to use a monoclonal antibody with dual binding specificity to link the toxic moiety directly to target cell antigens. This avoids chemical modification of the toxin and since the antibody and toxin can be administered separately, the targeting function will depend on the tumour-localising potential of the antibody alone rather than the less efficient localisation of the whole complex or conjugate. Toxins delivered in this way appear to have activity similar to that of conventional immunotoxins when tested in vitro (Raso & Griffin, 1981; Webb et al., 1985 Webb et al., , 1986 Glennie et al., 1988) .
In the case of two-chain toxins such as ricin, it has been suggested that the non-toxic B chain is involved in the transport of the toxic A chain into the target cell as well as its function of binding to cell surfaces by means of a lectin site (Thorpe & Ross, 1982; Thorpe, 1984) . Thus it has been shown that free B chain or B chain 'immunotoxins' can facilitate the uptake of A chain immunotoxins, rendering the combination more cytotoxic to target cells than the A chain immunotoxin alone (McIntosh et al., 1983; Vitetta et al., 1983 Vitetta et al., , 1984 . This report describes the cytotoxic properties of recombinant RTA (r-RTA) in combination with a bispecific monoclonal antibody, 636 , recognising RTA and carcinoembryonic antigen (CEA), and the potentiation of this activity by RTB added separately or included as part of the intact ricin molecule. The antibody was previously shown to mediate cytotoxicity by a non-toxic concentration of A chain purified from naturally occurring ricin, specifically against CEA expressing target cells ). (Price et al., 1987) . . The antibody was precipitated from hybrid-hydridoma culture supernatant by 50% saturation with ammonium sulphate and dialysed against 0.02 M pH 6.8 phosphate buffer. It was applied to a hydroxyapatite column and unbound protein was washed through with 0.02 M buffer, then antibody fractions were eluted with a 0.02 M to 0.3 M linear gradient of pH 6.8 phosphate buffer at 20 ml h-'. Fractions of 2 ml were tested for bispecific antibody by ELISA assays and a flow cytometric bridging assay employing CEA coated beads and fluorescein-labelled RTA min, then r-RTA was added in 0.025 ml medium. This was followed immediately by 0.025 ml RTB or culture medium, as appropriate. Control wells containing no antibody were treated with r-RTA or RTB alone, or medium alone. In some assays 0.025 ml whole ricin was used in place of r-RTA + RTB, and in this case it was preceded by 0.025 ml galactose at 24 mg ml-' (to give a final concentration of 3 mg ml 1). In certain assays ( Table I) the addition of RTB was delayed until 4 h after r-RTA, and cells were washed with culture medium before the application of r-RTA and before RTB. Washing was accomplished by completely removing supernatant containing the previously added reagent, filling the wells with culture medium and aspirating this medium, followed by replenishment with an appropriate volume of fresh medium before addition of the next reagent. Ricin, r-RTA, RTB and 636 antibody were used at varying concentrations according to the experiment, to produce the final concentrations indicated in the text in a total volume of 0.2 ml per well. All treatments were carried out in quadruplicate. The 
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Cytotoxicity mediated by r-RTA and bispecific antibody 636 Preliminary titrations were carried out to determine the effects on MKN45 cell survival of r-RTA, RTB, whole ricin and galactose (data not shown). From this information it was possible to select concentrations of each reagent which, used in isolation or in certain combinations, were low enough to produce no significant cytotoxicity against the target cells. These concentrations were then used to evaluate the potential of antibody 636 to augment cytotoxicity against MKN45.
r-RTA was non-toxic at 1 ytg ml-', and the chosen dose for the present experiments was 250 ng protein per ml. At this RTA concentration five different batches of 636 mediated highly significant and selective cytotoxicity against MKN45 as previously reported . Bispecific 636 was frequently used in control wells at up to 8 iLg ml-' in the absence of r-RTA, and never resulted in cytotoxicity on its own.
Influence of B chain on cytotoxicity by r-RTA and 636 Purified RTB was completely non-toxic to cells at a concentration of 1Ong ml-' and was used routinely at 2.5 ng ml-'. When combined at this dose with 250ngml-1' r-RTA the resultant cytotoxicity was approximately 60% to 70% above background, indicating a synergistic interaction between the two ricin fractions. At these concentrations the presence of 636 bispecific antibody produced a modest additive increase in cytotoxicity, as shown in Figure 1 . In this experiment, added RTB made the non-toxic concentration of r-RTA significantly cytotoxic for MKN45 cells. Increasing amounts of antibody also induced cytotoxicity on the part of the r-RTA, and cytotoxicity of combined r-RTA + RTB was enhanced by 636 to a degree roughly equivalent to the enhancement seen with r-RTA alone. When the antibody was used at a constant concentration of 4 fig ml-' and the RTB was titrated, a similar additive response was observed, up to the point where the effect of added RTB became maximal and therefore not subject to further increase (Figure 2 ). Thus at RTB concentrations of between 0.0001 and 0.01 ng ml-', which did not increase RTA cytotoxicity, a constant augmentation to about 35% cytotoxicity occurred due to 636. When RTB reached an active concentration (1 ng ml-1) the effect of 636 was additive, until augmentation to almost 100% cytotoxicity was achieved by RTB alone at 1Ong ml-' as well as by RTB + 636. The antigenic specificity of this additive response is shown in Figure 3 , where RTB + 636 can be seen to give greater r-RTA cytotoxicity than RTB against MKN45 cells, while there was no significant difference between RTB + 636 and RTB in the case of CEA-negative 791T cells. RTB (2.5 ng ml-') or RTB (2.5 ng ml-') plus 636 (8 gsg ml-') using MKN45 cells, additive responses of 636 and RTB were again seen (Figure 4 ). The r-RTA was titrated from 100 ng ml-' downwards, and at these concentrations augmentation of cytotoxicity by 636 was less pronounced than at 250 ng ml-RTA. However, RTB was more effective than 636 alone, and a mixture of 636 and RTB was the most effective treatment.
Effect of separating sequential treatments In some assays RTB treatment was delayed until 4 h after the addition of r-RTA to 636-coated cells, and in these experiments a comparison was made between cultures which were washed after 30 min incubation with 636, but before addition of r-RTA, and after 4 h r-RTA incubation but before addition of RTB, and cultures which received no washing or removal of the previous reagent before application of the next in the sequence (Table I ).
In these tests both 636 at 4 gg ml-I and RTB at 2.5 ng ml-' again significantly enhanced r-RTA cytotoxicity (P< 0.001), and the combination of 636, r-RTA and RTB was more effective than treatment with 636 + r-RTA (P < 0.025) or r-RTA + RTB (P<0.01). Combined 636, r-RTA and RTA concentration (ng ml-') Figure 4 Titration of r-RTA against RTB (2.5 ng ml-'), 636 (8 sg ml1'), or RTB (2.5 ng ml-') + 636 (8 jg ml-'), using MKN45 RTB was equally effective whether RTB was added immediately after r-RTA or 4 h later, and whether or not the previous reagent was removed and the cells washed at any or all of the reagent addition steps. None of the modifications produced results significantly different from the standard procedure in which all the reagents remained present until termination of the assay. This indicates that adequate 636 binding to MKN45 could occur within 30 min, and that accumulation of sufficient r-RTA/636 complex on (or in) the target cells was completed within the next 4 h. Furthermore, the enhancement of its internalisation and subsequent cytotoxic action by RTB was not dependent on reassociation of free r-RTA and RTB in the culture medium.
Effect of636 on cytotoxicity ofgalactose-blocked ricin Galactose at high concentrations was inhibitory to MKN45 cells, but at 3 mg ml1' (0.16 mM) it was virtually non-inhibitory and was sufficiently in excess of lectin sites on the B chain to reduce the cytotoxicity of 1 ng nml-whole ricin to about 5%. In the absence of galactose the 50% inhibitory concentration of ricin for MKN45 was about 0.1 ng ml-', and cytotoxicity at 1 ng ml' was almost 100%. Titration of 636 against galactose-blocked ricin at 1 ng ml-' produced increasing cytotoxicity against MKN45, until at 4;Lgmlml antibody it was restored to about 80% of the level seen with native ricin (Figure 5 ). Purified RTB (2.5 ng ml-') was similarly blocked with 3 mg ml-' galactose and tested in combination with r-RTA (250ngnml') and titrated 636, as also shown in Figure 5 . The previously demonstrated ability of RTB to augment r-RTA cytotoxicity was abolished by galactose, but full cytotoxic activity was restored in the presence of increasing amounts of 636.
The relative cytotoxic activities of r-RTA, blocked ricin and r-RTA + blocked RTB in the absence of 636 and in the presence of the highest 636 concentration tested (8 g ml-1) are compared in Figure 6 . This comparison puts into perspective the role of B chain in facilitating A chain cytotoxicity. Targeting with 636 antibody was effective with r-RTA alone, but the presence of an adequate amount of blocked B chain (either as part of intact ricin or as added RTB at 1% of the r-RTA concentration) significantly enhanced the efficiency of r-RTA targeting.
Discussion
Bispecific antibodies capable of targeting toxic moieties to tumour cells in vitro have been produced by chemical hydro- Comparison of augmented cytotoxicity against MKN45 using 8 pg ml-' 636 antibody. ( ) r-RTA (250 ng ml-'), (LII) galactose-blocked ricin (1 ng ml-'), (m) r-RTA (250 ng ml-') + galactose-blocked RTB (2.5 ng ml-'). Vertical bars on the histograms indicate standard errors. Cytotoxicity of all reagents was augmented by 636 compared with background (P<0.001), but augmentation was greater with blocked ricin or r-RTA + blocked RTB than with RTA alone (P <0.001).
lysis and reconstitution of two parental antibodies (Raso & Griffin, 1981; Glennie et al., 1988) and by production of hybridomas secreting monoclonal antibodies with dual specificity (Webb et al., 1985 (Webb et al., , 1986 Corvalan & Smith, 1987; Pimm et al., 1990) . In studies in which the toxic molecule was a plant toxin such as gelonin (Glennie et al., 1988) or RTA (Webb et al., 1985 (Webb et al., , 1986 , the reported efficiency of targeting by bispecific antibodies was comparable with that commonly observed with conventional immunotoxins in which toxin and anti-tumour monoclonal antibody are linked chemically (Davies & Crumpton, 1982; Moller, 1982) . In the case of bispecific antibody 636, significant cytotoxicity against MKN45 could be achieved at an RTA concentration as low as 4 x 10-9 M , which compares with independent experiments performed with chemically prepared conjugates between RTA and a different CEA-specific antibody (228), in which the most active conjugates killed 50% of MKN45 cells at a concentration of about 1.5 x 10-9 M RTA (Byers et al., 1988) . The augmentation of RTA activity by 636 was specific for CEA expression cells, and was dependent upon the dual specificity of the antibody; parental anti-CEA and anti-RTA monoclonal antibodies had no effect at all .
The cytotoxicity of RTA immunotoxins can be enhanced in several ways, notably the addition of lysosomotropic agents such as amines or proton ionophores or administration of RTB. Lysosomotropic agents appear to act by raising the pH of endosomes (Sandvig & Olsnes, 1982; Wileman et al., 1985) . This can result in the increased release of ricin following internalisation of ricin-ligand complexes, and it is possible that RTA is released from internalised immunotoxins in a similar manner. RTB can be administered in free form, or conjugated to the same targeting antibody as the RTA immunotoxin or any antibody recognising the immunotoxin conjugate (McIntosh et al., 1983; Vitetta et al., 1983 Vitetta et al., , 1984 , and is thought to aid cellular incorporation of immunotoxin by facilitating translocation through the cell membrane (McIntosh & Thorpe, 1984) . In cases where the targeted antigen is rapidly and efficiently internalised by the cell the lack of B chain may be advantageous but nonessential, but there are instances in which RTA immunotoxin is not readily incorported and the transport function of the B chain then becomes of major importance (McIntosh et al., 1983; Eccles et al., 1987 (Thorpe & Ross, 1982; Gregg et al., 1987; Cattel et al., 1988) . Galactose blocking can be very effective in aiding selectivity of ricin-antibody conjugates in vitro, and a galactose-blocked ricin anti-iodiotype antibody conjugate has been tested in vivo against a guinea pig B cell leukaemia line (Gregg et al., 1987) . The blocked ricin conjugate was therapeutic at 100-fold lower concentration than an equivalent RTA immunotoxin, but was also 100 times more toxic at equimolar doses, so that the overall therapeutic index was the same for both reagents.
The mechanism of action of RTB in potentiating RTA uptake has not been established. One assumption is that A and B chains reassociate to form intact toxin (McIntosh & Thorpe, 1984) which then presumably acts at the target site.
In the present studies r-RTA was used at a standard concentration of about 8 x 100-M, and RTB at a concentration of only 1% of this, so most of the r-RTA could not be involved in reassociation. If, however, all the RTB had reassociated with r-RTA on an equimolar basis, the resultant 'reconstituted ricin' could have been present in a quantity more than adequate to kill 100% of the target cells. Further titration of RTB (Figure 2 ) or r-RTA (Figure 4) ed immunotoxins, because the need to avoid lectin activity is fundamental to their design, and in published studies of the effect of RTB or RTB conjugates on RTA immunotoxins the B chain lectin site has not been blocked (McIntosh et al., 1983; Eccles et al., 1987; Vitetta et al., 1983 Vitetta et al., , 1984 . The experiments shown in Figure 5 , however, address this question. Whole ricin inactivated by blocking its B chain lectin site with galactose was rendered highly cytotoxic by the addition of 636 bispecific antibody, and there is no doubt that the B chain played an important role in this because the ricin was used at approximately 20 times lower molarity than the lowest concentration of RTA required for 636-mediated cytotoxicity . A mixture of intact RTB and r-RTA at the concentrations shown in highly cytotoxic, presumably because the RTB reassociates with sufficient r-RTA and mediates its entry into the cell by binding via the lectin site. When the lectin site was blocked with galactose as in Figure 5 , cytotoxicity was lost owing to the lack of binding ability. However, addition of 636 to induce binding of r-RTA to the cells restored the augmented level of cytotoxicity characteristic or r-RTA + unblocked RTB + 636. These results suggest that the B chain translocation function is still active when the lectin site is blocked, and therefore that the lectin site is not involved. This is in agreement with results of studies using intrinsically blocked whole ricinantibody conjugates (Cattel et al., 1988) . A blocked ricin immunotoxin had cytotoxic activity as high as that of an unblocked ricin conjugate, but was much more selective than the unblocked reagent. An RTA immunotoxin showed the same high selectivity, but was much less toxic than the blocked ricin conjugate.
The studies reported here demonstrate that a bispecific monoclonal antibody can provide an effective means of targeting r-RTA in vitro, and that the cytotoxicity observed is able to be potentiated by the addition of RTB. Moreover, the RTB is not required to possess an active lectin site. On theoretical grounds, there may be advantages to such a combination in comparison with a conventional immunotoxin when applied in vivo in a therapeutic context. The bispecific antibody may localise at the tumour site more efficiently than an RTA-antibody or blocked ricin-antibody conjugate, which is likely to be rapidly cleared from the circulation (Simmons et al., 1986; Byers et al., 1987 ). Subsequently administered RTA may then be trapped by the pre-localised antibody in higher quantities, before elimination, than could be delivered as an immunotoxin, particularly if recombinant RTA (lacking carbohydrate side chains) is used. Also, the possibility of using lectin-inactivated B chain to enhance the effect of localised A chain may be a safer approach than using intact B chain which could conceivably recombine with A chain to form active ricin. These potential advantages now require to be evaluated in a therapeutic model.
